Scarica l'app Stockscreener
3.27
3.82%
-0.13
Dopo l'orario di chiusura:
3.22
-0.05
-1.53%
Precedente Chiudi:
$3.40
Aprire:
$3.3779
Volume 24 ore:
13,898
Relative Volume:
0.07
Capitalizzazione di mercato:
$2.96M
Reddito:
-
Utile/perdita netta:
$-15.52M
Rapporto P/E:
-0.176
EPS:
-18.58
Flusso di cassa netto:
$-16.61M
1 W Prestazione:
-5.49%
1M Prestazione:
-21.39%
6M Prestazione:
-77.27%
1 anno Prestazione:
-92.14%
Intervallo 1D:
$3.26
$3.42
Intervallo di 1 settimana:
$3.21
$3.80
Portata 52W:
$3.19
$60.80
Revelation Biosciences Inc Stock (REVB) Company Profile
Nome
Revelation Biosciences Inc
Settore
Industria
Telefono
650-800-3717
Indirizzo
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Confronta REVB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
3.27 | 2.96M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Revelation Biosciences Inc Borsa (REVB) Ultime notizie
Revelation Biosciences Unveils Growth Strategy at Prestigious Roth Conference - StockTitan
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Joplin Globe
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Can Revelation's $6.5M Cash Runway Support Its Promising Gemini Program? - StockTitan
Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa
Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com
Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com
Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
Artificial Intelligence (AI) News Live Feed - StockTitan
Revelation Biosciences gets continued listing approval from Nasdaq - MSN
Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
Can This Biotech's New Kidney Disease Trial Transform CKD Treatment? Key Details - StockTitan
Larchmont broker accused of years-long insider trading scheme - Westfair Online
Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR
Revelation Biosciences stock hits 52-week low at $0.28 - MSN
REVB Start 1B Trial and Announces Split - MSN
REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Revelation Biosciences Inc (REVB) Has Strong Growth Prospects Through 2025 - Marketing Sentinel
Anthem man charged with insider trading - Foothills Focus
Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace
Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN
Revelation Bio Announces 1:16 Reverse Split, Advances CKD Drug Trial to Phase 1b - StockTitan
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com
Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - StockTitan
Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak
Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN
Broker, Traders Charged With $1M Insider Trading Scheme - Law360
Personal Finance - Business Wire
Several More Companies Propose Move From Delaware To Nevada - JD Supra
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire
Revelation Biosciences Inc (NASDAQ:REVB) Has Already Recovered 47.17%, But Another -4666.04% Drop Cannot Be Ruled Out. – Marketing Sentinel - Marketing Sentinel
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Nasdaq Grants Revelation Biosciences Inc. Continued Listing - BioSpace
Nasdaq grants Revelation Biosciences’ request for continued listing - MSN
Revelation Bio Secures Nasdaq Listing, Advances Kidney Disease Drug After FDA Green Light - StockTitan
Getty Images Rumored To Be In Merger Talks With Shutterstock: Retail Sees Potential Combination As ‘Win-Win’ Proposition - MSN
Revelation Biosciences Inc Azioni (REVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):